PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?

Decroos, Amandine; Giustiniani, Jerome; Pelletier, Laura; Ingen-Housz-Oro, Saskia; Gaulard, Philippe; Ortonne, Nicolas

Decroos, Amandine; Giustiniani, Jerome; Pelletier, Laura; Ingen-Housz-Oro, Saskia; Gaulard, Philippe; Ortonne, Nicolas.

Afiliação

Decroos A; Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France.
Giustiniani J; Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France.
Pelletier L; Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France.
Ingen-Housz-Oro S; Dermatology department, APHP, Henri Mondor hospital, Paris, France.
Gaulard P; Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France; Pathology department, APHP, Henri Mondor hospital, Paris, France.
Ortonne N; Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France; Pathology department, APHP, Henri Mondor hospital, Paris, France.

Eur J Cancer ; 156 Suppl 1: S14-S15, 2021 Oct.

Article em En | MEDLINE | ID: mdl-34649644

Palavras-chave

PD1; Sézary syndrome; antibody-dependent cell cytotoxicity; antibody-dependent cell phagocytosis; cell line

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google